It could be crazy!Based on Intermune acquisition, PBI-4050 could already worth $ 7B if successfull in IPF, an orphan disease.
Now, how much it can worth in a huge market, when you have a different mechanism of actions from the usual drugs, orally active and less side effect?
I won't put a number, but if it goes to the market in 2 or 3 applications, it will be crazy....